Actively Recruiting
Phase 1b2 Study of MK-1045 Immunotherapy for Treating Follicular and Diffuse Large B-Cell Non-Hodgkin Lymphoma
Led by Merck Sharp & Dohme LLC · Updated on 2026-08-07
280
Participants Needed
30
Research Sites
39 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating MK-1045, an immunotherapy, in people with two types of non-Hodgkin lymphoma NHL follicular lymphoma FL, which grows slowly, and diffuse large B-cell lymphoma DLBCL, which grows more quickly. NHL is a cancer of the lymphatic system causing swollen lymph nodes. This study aims to assess the safety and tolerability of MK-1045 and to see if it can shrink or eliminate these lymphomas. Participants are randomly assigned to one of four groups receiving different doses or methods of MK-1045 administration. Dosages A, B, and D are given by intravenous IV infusion, while Dosage C is given by subcutaneous SC injection. Treatment lasts for up to approximately one year or until participants stop treatment for any reason. During the study, participants will be monitored for adverse events and treatment side effects, with measurements including tumor response using specific criteria. Blood levels of MK-1045 will also be tracked. The study involves regular visits for infusions and assessments. Participant safety and treatment effects will be followed for up to about 49 months in total.
CONDITIONS
Brief Title
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
